South Korea, US Discuss Chip Investments Amid Tariff Plans 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Add as a preferred source on Google
FARMINGDALE, N.Y., Feb. 27, 2018 -- Misonix, Inc. (Nasdaq:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the Canaccord Genuity Musculoskeletal Conference held at the Sheraton hotel in New Orleans, Louisiana on Tuesday, March 6, 2018. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, will be making a company presentation at 2:30 p.m. CT (3:30 p.m. ET) that day and will be available to meet with institutional investors in one-on-one meetings throughout the day.
The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at [email protected].
About Misonix, Inc.
Misonix, Inc. (Nasdaq:MSON) designs, develops, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix's proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s 59-year history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.
Contact:
Joe Dwyer
Chief Financial Officer
Misonix, Inc.
631-927-9113
Joseph Jaffoni, Norberto Aja, Jennifer Neuman
JCIR
212-835-8500 or [email protected]
